Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye disease
Biotech
Opthea ramps up cuts to 85% of staff, including CEO
Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures, but the company isn’t ready to give up.
James Waldron
Aug 19, 2025 7:35am
Boehringer inks another eye disease deal, this time with Palatin
Aug 18, 2025 10:30am
Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out
Jul 24, 2025 5:00am
Cloudbreak plots phase 3 after eye drop passes midstage test
Jul 21, 2025 4:35am
Okyo's eye drops reduce neuropathic eye pain in phase 2 win
Jul 16, 2025 11:57am
Glaukos nets EU green lights for glaucoma surgery micro-stents
Jun 27, 2025 1:55pm
